price picking up, page-6

I think the company is doing a good job of keeping the lid on. This really surprises me because they've been no good at it in the past.

If the results of the recent trial were not promising, i.e. not holding out the prospect of a near-term partnering deal with a Pfizer, Astra Zenica, Glaxo or Lilly, we would be looking at a gap down to 5 or 6 cents a share.

These shares would be selling at a DISCOUNT to cash on the prospect of a burn and die scenario with little or nothing coming back to shareholders.

If the word were out of a positive result, we would be in the high teens.

Ergo, the market is in the dark.